 |
 Video: What is a Stock Split?
|
|
|
| Myovant Sciences is a biopharmaceutical company. Co. has two U.S. Food and Drug Administration-approved products, which consist of: ORGOVYX® (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with prostate cancer; and MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), an oral GnRH treatment for the management of heavy menstrual bleeding associated with uterine fibroids. Co.'s MYFEMBREE is being evaluated for contraceptive ability in women with heavy menstrual bleeding associated with uterine fibroids or endometriosis-associated pain who are 18 to 50 years of age and at risk for pregnancy. According to our MYOV stock split history records, MYOV has had 0 splits. | |
|
MYOV (MYOV) has 0 splits in our MYOV stock split history database.
Looking at the MYOV stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MYOV shares, starting with a $10,000 purchase of MYOV, presented on a split-history-adjusted basis factoring in the complete MYOV stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/04/2016 |
|
| End date: |
03/09/2023 |
|
| Start price/share: |
$12.30 |
|
| End price/share: |
$26.98 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
119.35% |
|
| Average Annual Total Return: |
13.18% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$21,937.13 |
|
| Years: |
6.35 |
|
|
|
|
|
